WASHINGTON - U.S. pharmaceutical giant Pfizer Inc. said Tuesday that its experimental antiviral pill against COVID-19 has shown nearly 90 percent efficacy in preventing hospitalization or death in high-risk patients, citing final study results.
Sorry. This article is no longer available.
Sorry, this article was first published more than three months ago and is temporarily unavailable.
Once the upcoming introduction of a paid membership system is fully operational, paid members will have access to all our stories.
Free Membership Provides
Newsletter from Editorial Team and access to archive articles from past three months.
By continuing, you agree to the Terms of Use,
and Privacy Policy.
